Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.03 USD | -1.30% | -4.72% | -7.20% |
04-24 | Gain Therapeutics, Inc. Announces Positive Results from the Single Ascending Dose Part of the Phase 1 Clinical Trial of GT-02287 | CI |
04-08 | Gain Therapeutics Names Gene Mack as CFO | MT |
Sales 2024 * | 666K 53.31M | Sales 2025 * | 144K 11.51M | Capitalization | 49.15M 3.93B |
---|---|---|---|---|---|
Net income 2024 * | -21M -1.68B | Net income 2025 * | -28M -2.24B | EV / Sales 2024 * | 73.8 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 342 x |
P/E ratio 2024 * |
-2.65
x | P/E ratio 2025 * |
-2.57
x | Employees | 31 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 83.55% |
1 day | -1.30% | ||
1 week | -4.72% | ||
Current month | -19.63% | ||
1 month | -18.77% | ||
3 months | -19.20% | ||
6 months | +4.84% | ||
Current year | -7.20% |
Managers | Title | Age | Since |
---|---|---|---|
Matthias Alder
CEO | Chief Executive Officer | 59 | 18/10/21 |
Chief Tech/Sci/R&D Officer | - | 28/02/19 | |
Eric Richman
BRD | Director/Board Member | 63 | 30/06/20 |
Members of the board | Title | Age | Since |
---|---|---|---|
Dov Goldstein
BRD | Director/Board Member | 56 | 31/12/20 |
Eric Richman
BRD | Director/Board Member | 63 | 30/06/20 |
Matthias Alder
CEO | Chief Executive Officer | 59 | 18/10/21 |
Date | Price | Change | Volume |
---|---|---|---|
26/04/24 | 3.03 | -1.30% | 179,297 |
25/04/24 | 3.07 | -3.76% | 142,421 |
24/04/24 | 3.19 | -5.90% | 146,812 |
23/04/24 | 3.39 | +6.94% | 66,437 |
22/04/24 | 3.17 | -0.31% | 53,675 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-7.20% | 49.15M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- GANX Stock